The Criteria for the clinical use of immunoglobulin in Australia (the Criteria) undergoes periodic review to reflect the latest scientific evidence and expert advice from our National Immunoglobulin Governance Advisory Committee and its Specialist Working Groups.
This page summarises the changes to the Criteria which were implemented in 2021. Changes are applied immediately to new authorisations and to existing authorisations at the next continuing treatment request, unless otherwise stated. For more information about any of these changes, please contact the Ig Governance team at IgGovernance@blood.gov.au.
July 2021
Kawasaki disease – Version 3.1
- New evidence item introduced to capture whether the presentation of Kawasaki-like symptoms are linked to COVID-19.
- Age limitation removed to allow young adults with Kawasaki disease to access Ig.
April 2021
Vaccine induced immune thrombotic thrombocytopenia (VITT) / Vaccine induced prothrombotic immune thrombocytopenia (VIPIT) – Version 3.0
- New condition added to the Criteria on a temporary basis.
Last updated: 03 Feb 2026